Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free IMCC Stock Alerts

IM Cannabis (IMCC) Competitors

IM Cannabis logo
$3.09 -1.14 (-26.95%)
As of 04:00 PM Eastern
Compare

IMCC vs. CANF, ASLN, NMTR, CMND, and EVFM

Should you buy IM Cannabis stock or one of its competitors? IM Cannabis's main competitors and comparable companies include Can-Fite BioPharma (CANF), ASLAN Pharmaceuticals (ASLN), 9 Meters Biopharma (NMTR), Clearmind Medicine (CMND), and Evofem Biosciences (EVFM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does IM Cannabis compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, IM Cannabis had 5 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 6 mentions for IM Cannabis and 1 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Can-Fite BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IM Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Can-Fite BioPharma has higher earnings, but lower revenue than IM Cannabis. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K5.87-$7.63M-$22.80N/A
IM Cannabis$39.17M0.02-$8.10M-$60.66N/A

Can-Fite BioPharma has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Can-Fite BioPharma's return on equity of 0.00% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
IM Cannabis -39.62%-585.96%-58.32%

Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 1,881.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Can-Fite BioPharma beats IM Cannabis on 11 of the 15 factors compared between the two stocks.

How does IM Cannabis compare to ASLAN Pharmaceuticals?

IM Cannabis (NASDAQ:IMCC) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

IM Cannabis has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than ASLAN Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.17M0.02-$8.10M-$60.66N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

In the previous week, IM Cannabis had 6 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 6 mentions for IM Cannabis and 0 mentions for ASLAN Pharmaceuticals. IM Cannabis' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
IM Cannabis Neutral
ASLAN Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

ASLAN Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. IM Cannabis' return on equity of -585.96% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-39.62% -585.96% -58.32%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

IM Cannabis beats ASLAN Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does IM Cannabis compare to 9 Meters Biopharma?

IM Cannabis (NASDAQ:IMCC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

9 Meters Biopharma has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. 9 Meters Biopharma's return on equity of -584.97% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-39.62% -585.96% -58.32%
9 Meters Biopharma N/A -584.97%-159.45%

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IM Cannabis has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than 9 Meters Biopharma. IM Cannabis is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.17M0.02-$8.10M-$60.66N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

In the previous week, IM Cannabis had 6 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 6 mentions for IM Cannabis and 0 mentions for 9 Meters Biopharma. IM Cannabis' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company Overall Sentiment
IM Cannabis Neutral
9 Meters Biopharma Neutral

Given 9 Meters Biopharma's higher probable upside, analysts plainly believe 9 Meters Biopharma is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

9 Meters Biopharma beats IM Cannabis on 7 of the 13 factors compared between the two stocks.

How does IM Cannabis compare to Clearmind Medicine?

IM Cannabis (NASDAQ:IMCC) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Clearmind Medicine has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Clearmind Medicine's return on equity of -88.53% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-39.62% -585.96% -58.32%
Clearmind Medicine N/A -88.53%-61.62%

Clearmind Medicine has lower revenue, but higher earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.17M0.02-$8.10M-$60.66N/A
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A

In the previous week, IM Cannabis had 4 more articles in the media than Clearmind Medicine. MarketBeat recorded 6 mentions for IM Cannabis and 2 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 0.67 beat IM Cannabis' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IM Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Clearmind Medicine
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

IM Cannabis has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Clearmind Medicine beats IM Cannabis on 7 of the 12 factors compared between the two stocks.

How does IM Cannabis compare to Evofem Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Evofem Biosciences has higher earnings, but lower revenue than IM Cannabis. Evofem Biosciences is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.09$52.98M-$0.13N/A
IM Cannabis$39.17M0.02-$8.10M-$60.66N/A

In the previous week, IM Cannabis had 6 more articles in the media than Evofem Biosciences. MarketBeat recorded 6 mentions for IM Cannabis and 0 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company Overall Sentiment
Evofem Biosciences Neutral
IM Cannabis Neutral

Evofem Biosciences has a beta of -1.3, indicating that its share price is 230% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

IM Cannabis has a net margin of -39.62% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
IM Cannabis -39.62%-585.96%-58.32%

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

IM Cannabis beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCC vs. The Competition

Export
MetricIM CannabisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$649K$12.51B$7.26B$13.23B
Dividend YieldN/A2.64%2.53%12.80%
P/E Ratio-0.05794.81275.5625.79
Price / Sales0.02796.68693.67102.99
Price / CashN/A15.0828.0434.72
Price / Book-0.2110.5710.566.36
Net Income-$8.10M$2.82B$3.49B$358.17M
7 Day Performance79.65%-0.36%-0.23%0.54%
1 Month Performance-8.69%-1.19%-2.80%-2.95%
1 Year Performance-94.69%4.01%18.25%6.08%

IM Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCC
IM Cannabis
0.2689 of 5 stars		$3.09
-27.0%		N/A-92.7%$880K$39.17MN/A44
CANF
Can-Fite BioPharma
1.7148 of 5 stars		$2.21
+0.9%		$44.00
+1,891.0%		-82.8%$1.45M$405KN/A8
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat		N/AN/A$1.23M$12MN/A30
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
CMND
Clearmind Medicine
1.565 of 5 stars		$1.02
-4.2%		N/A-99.8%$1.04MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IMCC) was last updated on 9/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel